Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer

Japanese Journal of Clinical Oncology

Volumn 43, Issue 2, 2013, Pages 193-199

  Iwasaki, Kazuhiro ^a   Obara, Wataru ^a   Kato, Yoichiro ^a   Takata, Ryo ^a   Tanji, Susumu ^a   Fujioka, Tomoaki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemo urology; Urologic med; Urology

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; METOCLOPRAMIDE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL EVALUATION; CYSTECTOMY; DRUG SAFETY; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; GLOMERULUS FILTRATION RATE; HUMAN; ILEUS; LIVER DYSFUNCTION; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; RECTUM INJURY; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURGICAL INFECTION; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NAUSEA; NEOADJUVANT THERAPY; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE; VOMITING;

EID: 84873418606     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys213     Document Type: Article

References (31)

1. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001;19:666-75.
2. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66.
3. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
4. Dash A, Pettus JA 4th, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008;113:2471-7.
5. Weight CJ, Garcia JA, Hansel DE, et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder. Cancer 2009;115:792-9.
6. Scosyrev E, Messing EM, van Wijngaarden E, et al. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer 2012;118:72-81.
7. Waxman J, Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 1993;19:21-5.
8. Xu N, Zhang XC, Xiong JP, et al. A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium. BMC Cancer 2007;7:98.
9. Bamias A, Moulopoulos LA, Koutras A, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 2006;106:297-303.
10. Eilers H, Liu KD, Gruber A, Niemann CU. Chronic kidney disease: implications for the perioperative period. Minerva Anestesiol 2010;76:725-36.
11. Imai E, Horie M, Yamagata K, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res 2008;31:433-41.
12. Maeda T, Takahashi A, Hirobe M, et al. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder. Hinyokika Kiyo 2007;53:213-9.
13. Sagaster P, Flamm J, Flamm M, et al. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer. Eur J Cancer 1996;32:1320-4.
14. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8.
15. Roberts JT, von der Maase H, Sengelø L, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 2006;17:118-22.
16. Kaneko G, Kikuchi E, Matsumoto K, et al. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer. Jpn J Clin Oncol 2011;41:908-14.
17. Dogliotti L, Cartení G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007;52:134-41.
18. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 2012;23:406-10.
19. Linardou H, Aravantinos G, Efstathiou E, et al. Phase II study of Hellenic Co-operative Oncology Group. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 2004;64:479-84.
20. Hudson E, Lester JF. Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature. Eur J Cancer Care 2010;19:324-8.
21. Stenzl A, Cowan NC, De Santis M, et al. European Association of Urology (EAU). Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18.
22. Montie JE, Clark PE, Eisenberger MA, et al. Bladder cancer. National Comprehensive Cancer Network. J Natl Compr Canc Netw 2009;7:8-39.
23. Committee for Establishment of the Clinical Practice Guidelines for the Management of Bladder Cancer and the Japanese Urological Association. Evidence-based clinical practice guidelines for bladder cancer (summary, JUA 2009 Edition). Int J Urol 2010;17:102-24.
24. Koie T, Ohyama C, Hashimoto Y, et al. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. Int J Clin Oncol 2012. Epub ahead of print.
25. Solsona E, Iborra I, Rubio J, et al. Late oncological occurrences following radical cystectomy in patients with bladder cancer. Eur Urol 2003;43:489-94.
26. Yaguchi T, Sumimoto H, Kudo-Saito C, et al. The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol 2011;93:294-300.
27. Kirkova J, Rybicki L, Walsh D, Aktas A. Symptom prevalence in advanced cancer: age, gender, and performance status interactions. Am J Hosp Palliat Care 2012;29:139-45.
28. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173-81.
29. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11:2625-36.
30. Takata R, Katagiri T, Kanehira M, et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 2007;98:113-7.
31. Kato Y, Zembutsu H, Takata R, et al. Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling. Exp Ther Med 2011;2:47-56.